JPMorgan Chase & Co. Purchases 38,550 Shares of Incyte Co. (NASDAQ:INCY)

JPMorgan Chase & Co. boosted its position in Incyte Co. (NASDAQ:INCY – Free Report) by 13.

5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 323,640 shares of the biopharmaceutical company’s stock after acquiring an additional 38,550 shares during the period. JPMorgan Chase & Co.



owned 0.17% of Incyte worth $22,354,000 at the end of the most recent quarter. A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company.

Sound Shore Management Inc. CT grew its position in shares of Incyte by 98.4% during the 4th quarter.

Sound Shore Management Inc. CT now owns 1,201,089 shares of the biopharmaceutical company’s stock worth $82,959,000 after buying an additional 595,741 shares during the period. Long Corridor Asset Management Ltd acquired a new stake in Incyte during the 4th quarter worth $22,793,000.

Candriam S.C.A.

raised its position in shares of Incyte by 27.8% during the 4th quarter. Candriam S.

C.A. now owns 1,034,652 shares of the biopharmaceutical company’s stock valued at $71,463,000 after acquiring an additional 224,919 shares during the last quarter.

LBP AM SA acquired a new position in shares of Incyte in the 4th quarter valued at $13,905,000. Finally, Los Angeles Capital Management LLC boosted its position in shares of Incyte by 94.1% in the 4th quarter.

Los Angeles Capital Management LLC now owns 407,201 shares of the biopharmaceutical company’s stock worth $28,125,000 after purchasing an additional 197,406 shares during the last quarter. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at IncyteIn other news, EVP Steven H. Stein sold 12,352 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $72.

69, for a total transaction of $897,866.88. Following the sale, the executive vice president now owns 66,967 shares in the company, valued at $4,867,831.

23. This represents a 15.57 % decrease in their position.

The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Barry P. Flannelly sold 19,807 shares of the firm’s stock in a transaction on Friday, March 14th.

The shares were sold at an average price of $67.69, for a total transaction of $1,340,735.83.

Following the completion of the transaction, the executive vice president now directly owns 33,567 shares of the company’s stock, valued at $2,272,150.23. This represents a 37.

11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 46,827 shares of company stock valued at $3,322,618.

Insiders own 17.60% of the company’s stock. Incyte Price PerformanceNASDAQ INCY opened at $58.

86 on Thursday. The firm’s 50 day moving average is $66.90 and its 200-day moving average is $69.

70. The company has a quick ratio of 1.94, a current ratio of 1.

97 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $11.

39 billion, a PE ratio of 218.01, a price-to-earnings-growth ratio of 0.41 and a beta of 0.

89. Incyte Co. has a 12-month low of $50.

35 and a 12-month high of $83.95. Incyte (NASDAQ:INCY – Get Free Report) last issued its quarterly earnings results on Monday, February 10th.

The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.

48). Incyte had a net margin of 0.77% and a return on equity of 0.

05%. Equities research analysts anticipate that Incyte Co. will post 4.

86 earnings per share for the current fiscal year. Analyst Ratings ChangesINCY has been the subject of a number of recent analyst reports. Wells Fargo & Company upped their price objective on Incyte from $68.

00 to $70.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. Guggenheim downgraded shares of Incyte from a “buy” rating to a “neutral” rating and set a $92.

00 price target on the stock. in a research report on Tuesday, March 18th. JMP Securities restated a “market perform” rating on shares of Incyte in a report on Tuesday, February 11th.

Royal Bank of Canada cut their target price on shares of Incyte from $70.00 to $68.00 and set a “sector perform” rating on the stock in a report on Tuesday, February 11th.

Finally, UBS Group assumed coverage on shares of Incyte in a report on Tuesday, December 17th. They issued a “neutral” rating and a $77.00 price target for the company.

One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $74.

88.Read Our Latest Research Report on INCYAbout Incyte (Free Report)Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.

Featured ArticlesFive stocks we like better than Incyte5 discounted opportunities for dividend growth investorsQuantum Computing: The $6.5 Billion Opportunity You Can’t IgnoreHigh Dividend REITs: Are They an Ideal Way to Diversify?Are Tariffs Threatening Disney’s Comeback Story?Business Services Stocks InvestingIs Alphabet a Generational Buying Opportunity at These Levels?Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co.

(NASDAQ:INCY – Free Report)..